All In Biotech

NDA 210922 · Alnylam Pharms INC

Onpattro

Patisiran Sodium · Intravenous

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 10, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

11

5 Phase 3, 0 recruiting

FAERS reports

2,828

1,915 serious, 419 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 8, 2025.

ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. ONPATTRO contains a transthyretin-directed small interfering RNA and is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Mechanism: Patisiran is a double-stranded siRNA that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 13, 2023 Supplement 12 · Efficacy OrphanLetterLabel
  • Aug 10, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • ONPATTRO · PATISIRAN SODIUM EQ 10MG BASE/5ML (EQ 2MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Patisiran" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death270
  • product dose omission issue179
  • fatigue174
  • hospitalisation132
  • infusion related reaction129
  • asthenia117
  • fall116
  • intentional dose omission115
  • cardiac failure101
  • dyspnoea94
  • malaise89
  • inappropriate schedule of product administration85

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201841
2019514
2020332
2021484
2022532
2023413
2024295
2025145
202672

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Onpattro (Patisiran Sodium,Lipid Complex)

2024 spending

$7.0M

Beneficiaries

25

248 claims

Per beneficiary

$279,702

$1,972.51 per unit

View as table
YearSpending
2020$5,565,175
2021$11,429,867
2022$16,396,639
2023$9,169,028
2024$6,992,561

Part B: Onpattro (Patisiran Sodium,lipid Complex) · HCPCS J0222

2024 spending

$24.0M

Beneficiaries

84

944 claims

Per beneficiary

$286,149

2024 ASP limit $99.35 per unit

View as table
YearSpending
2020$60,532,022
2021$82,896,519
2022$98,102,746
2023$37,700,003
2024$24,036,500

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 40 on PubMed

Sponsor: Alnylam Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.